About Products Value to Hospital Patients Resources News Contact Us is now part of Cardiva Medical is excited to be part of Haemonetics to expand our reach! LEARN MORE Safe. Simple. Guaranteed. 5–7F Arterial & Venous Closure For Coronary, Peripheral and Interventional Neurology Procedures Early Ambulation. Simple. Proven. 6-12F (15F max outer diameter) Venous Vascular Closure Designed for EP Procedures. Proven by EPs. The only FDA-approved closure device for use following cardiac ablations* Videos See VASCADE and VASCADE MVP procedures, and physician and patient perspectives. Clinical Data Review clinical data that demonstrates efficacy and patient benefits. Instructions Access VASCADE and VASCADE MVP instructions for use. Brochures Marketing support materials for VASCADE and VASCADE MVP. Media Kit Access photos, logos and press release materials. For Hospitals Reducing Complications and Improving Hospital Efficiencies LEARN MORE For Patients Safe and Effective Vascular Closure LEARN MORE LATEST NEWS JULY 16 Cardiva Medical Announces First... READ MORE JULY 16 Cardiva Medical Announces First... READ MORE JULY 14 Cardiva Medical Announces $45 Million... READ MORE Call us today Toll Free: (in the U.S.) 1-866-602-6099 Need to speak with a Cardiva Representative? REQUEST A CALL Directions 1615 Wyatt Drive Santa Clara, CA 95054 Email Us customerservice@ cardivamedical.com About Us Products Value to Hospital Patients Resources News Contact Us IFUs * Cardiac ablations requiring two or more access sites within the same limb. See VASCADE MVP IFU 3972 Indications for Use © 2021 Cardival Medical, Inc. VASCADE®, VASCADE MVP®, and Cardiva CATALYST® are registered trademarks of Cardiva Medical, Inc.. Document Portal Privacy Policy Site Map

About Products Value to Hospital Patients Resources News Contact Us PATENTS OVERVIEW ETHICS PATENTS The VASCADE® product is covered by one or more of the following US patents: US 5,782,860 US 5,922,009 US 6,056,769 US 7,691,127 US 8,747,435 US 8,911,472 US 9,439,637 The CATALYST® II product is covered by one or more of the following US patents: US 5,782,860 US 5,922,009 US 6,056,769 US 7,691,127 US 7,993,366 US 9,179,897 US 9,597,066 The CATALYST® III product is covered by one or more of the following US patents: US 5,782,860 US 5,922,009 US 6,056,769 US 7,691,127 US 7,993,366 US 8,747,435 Cardiva Company Milestones VASCADE MVP® receives FDA approval for 6-12F Inner Diameter (ID) multi-vessel venous vascular closure Antegrade Study results published in Vascular Disease Management in 2018 VASCADE® receives FDA approval for use in femoral veins in 2018 VASCADE VCS approved by the FDA in 2013 VASCADE VCS approved for CE Mark in Europe in 2012 CATALYST III received 510(k) clearance in 2009 CATALYST II approved for CE Mark in Europe in 2008 CATALYST II received 510(k) clearance in 2007 About Us Products Value to Hospital Patients Resources News Contact Us IFUs © 2021 Cardival Medical, Inc. VASCADE®, VASCADE MVP®, and Cardiva CATALYST® are registered trademarks of Cardiva Medical, Inc.. Document Portal Privacy Policy Site Map